on Biophytis (EPA:ALBPS)
Biophytis Showcases Innovations at BIO International 2025
Biophytis, a leader in transformative therapies for obesity, sarcopenia, and longevity, successfully participated in the BIO International Convention 2025. The event took place at the Boston Convention & Exhibition Center from June 16-19, 2025, attracting 20,000 industry leaders and fostering collaboration and scientific exchange.
At the convention, Biophytis highlighted its innovative approaches to critical health challenges. The company's therapies target obesity, age-related muscle wasting (sarcopenia), and aging mechanisms, positioning them at the forefront of precision medicine.
Biophytis presented progress in obesity innovation with its Phase 2 trial for BIO101, aiming to restore mobility for those with obesity. In sarcopenia, BIO101 shows potential with strong Phase 2 results, with plans for Phase 3. In longevity, the company focuses on therapies enhancing lifespan and healthspan, integrating new technologies and AI.
Post-convention, Biophytis seeks strategic partnerships to advance the global commercialization of its therapies.
R. H.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all Biophytis news